Updating the HHS Secretary's Advisory Committee on Genetics, Health, and Society regarding New York’s regulatory stance on consumer genomics firms, a health department official said companies that obtain raw data from an analytical testing facility and send a report to an ordering practitioner are considered laboratories.
Seahorse acquired the maker of the SimCell System, a fully integrated cell culture automation system used for selecting clones, optimizing media, and determining the best process conditions for protein manufacturing, for an undisclosed sum. It also raised $6 million in funding from VC investors.
Top executives last week from Alexandria Real Estate Equities, BioMed Realty Trust, and HCP said life-sci shops are increasingly skittish about leasing new space for the long term, leading the REITs to reduce spending on construction and renovation projects this year.
Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.
Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.